Abstract 1657P
Background
Pancreatic ductal adenocarcinoma (PDAC) represents the fourth highest rate of cancer-related deaths worldwide. The absence of early symptoms, early metastasis, and inefficient systemic therapies lead to a fatal prognosis for PDAC patients. Currently, surgical resection is the only curative option. However, it is often linked to severe postoperative complications and a considerable tumor recurrence rate. Therefore, identifying the resistance mechanisms of PDAC and developing targeted therapies is crucial.
Methods
Mutant KRAS and its effector Pdk1 play a major role in PDAC carcinogenesis. Previous works showed that Pdk1 deletion causes impairment of PDAC cell proliferation in vitro and in vivo. However, a minor subpopulation of cells continues to proliferate. To investigate this resistance, a genome wide CRISPR/Cas9 knockout screen was performed. Members of SAGA and Mediator complexes were among the top hits of the screen. The CRISPR knockouts of these genes were generated in the bulk PDAC epithelial cell line and in two single cell clones - one resistant and one sensitive to Pdk1 deletion. Clonogenic assays were performed to analyze the proliferation of the knocked-out cells, while RNA sequencing was conducted to investigate the differentially expressed genes.
Results
In the CRISPR/Cas9 knockout screen, members of SAGA and Mediator complexes showed enrichment in Pdk1 deletion resistant clones. Amongst all hits, significant proliferation of the Usp22- and Atxn7L3- as well as Med13- and Med16-knockout in the Pdk1 deleted PDAC cells was observed, with the strongest effect in the resistant clone. Several enhanced or downregulated hallmark pathways were observed in the knocked-out cells, providing insight into possible resistance mechanisms of the PDAC.
Conclusions
The results of the RNA sequencing of both SAGA and Mediator knocked-out cells showed an enhancement of the Hedgehog signalling, a pathway reported in the initiation of a growing number of cancers. The results of this research suggest furthermore, that the loss of the connecting units Atxn7L3 and Med16 promotes an unhinged transcription activity of the enzymatically active SAGA and Mediator complexes and leads to an enhanced PDAC cell proliferation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
German Research Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1665P - Prognostic impact of diabetes and antidiabetic medication in pancreatic cancer patients
Presenter: Alexander Friedrich
Session: Poster session 22
1667P - Clinical and molecular features of young onset pancreatic adenocarcinoma
Presenter: Maxime Remond
Session: Poster session 22
1668P - Prevalence and management of pancreatic ductal adenocarcinoma (PDAC) over a decade in France: A population-based study
Presenter: Léo Mas
Session: Poster session 22
1670P - Tumoral and non-tumoral thrombosis associated with pancreatic ductal adenocarcinoma (PDAC): Survival impact, assessment of predictive scales and rethrombosis
Presenter: Alejandra Cardozo
Session: Poster session 22
1671P - Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry
Presenter: Teresa Macarulla
Session: Poster session 22
1673P - Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study
Presenter: Sofie Olsson Hau
Session: Poster session 22
1674P - VILP registry of patients with metastatic pancreatic cancer treated with pegylated liposomal irinotecan plus 5-fluoroucil and leucovorin in the Czech Republic
Presenter: Stanislav Batko
Session: Poster session 22
1675P - Diagnostic performance of blood-based DNA methylation assay using epigenetic-specific peptide nucleic acid in pancreatic adenocarcinoma
Presenter: Hongsik Kim
Session: Poster session 22
1676P - Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
Presenter: Nunticha Umpawan
Session: Poster session 22